ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
WINSTON-SALEM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2026 and provided business highlights and upcoming milestones.
Covered in this story
Call it yourself
No calls on $PROK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on ProKidney →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.